Welcome to our dedicated page for Minerva Neurosci SEC filings (Ticker: NERV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Minerva Neurosciences, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company focused on central nervous system disorders. Form 8-K reports cover results of operations and financial condition, Regulation FD materials, roluperidone clinical-development disclosures, annual meeting timing, and material corporate events involving officers, directors, compensation arrangements, and governance.
Definitive proxy statements describe stockholder meeting procedures, board elections, voting matters, executive compensation, and corporate-governance practices. The filings also identify Minerva’s common stock listed on The Nasdaq Capital Market and provide formal disclosure around financing arrangements, board composition, and the company’s roluperidone program for negative symptoms of schizophrenia.
Minerva Neurosciences, Inc. reported that SVP, CFO and Secretary Frederick W. Ahlholm received a grant of stock options covering 680,000 shares of Common Stock. The options have an exercise price of $4.6800 per share and expire on June 2, 2036.
According to the footnote, the option vests 25% on June 3, 2027 and then in equal quarterly installments over three years. Following this grant, Ahlholm holds 680,000 stock options directly, and the filing does not show any related share sales or purchases.
Minerva Neurosciences CEO Remy Luthringer received a new stock option grant. The award covers 1,690,700 options to buy Minerva common stock at an exercise price of $4.68 per share. The option vests 25% on June 3, 2027, with the remainder vesting in equal quarterly installments over the following three years, and expires on June 2, 2036.
Minerva Neurosciences director Fouzia Laghrissi-Thode received a stock option grant covering 50,000 shares of common stock. The option has an exercise price of $4.68 per share and expires on June 2, 2036. It vests in four equal quarterly installments, with the first 12,500 shares vesting three months after June 3, 2026 and additional 12,500-share tranches vesting every three months thereafter, subject to her continued service as a non-employee director. This filing reports a compensation-related award rather than any open-market buying or selling of shares.
Minerva Neurosciences director David Kupfer received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $4.68 per share and expire on June 2, 2036. Following this award, he holds options for 50,000 shares directly.
The grant vests in four equal quarterly installments, with one-quarter vesting three months after June 3, 2026 and an additional quarter vesting every three months thereafter, subject to his continued service as a non-employee director on each vesting date.
Minerva Neurosciences director Inderjit Kaul received a new stock option grant as equity compensation. The award covers 50,000 shares of common stock at an exercise price of $4.68 per share and is held directly.
The option vests in four equal quarterly installments, with one quarter of the total shares vesting three months after June 3, 2026 and the remaining quarters vesting every three months thereafter, provided Kaul continues to serve as a non-employee director on each vesting date. Following this grant, Kaul holds options covering 50,000 shares, and there were no open-market purchases or sales reported.
Minerva Neurosciences, Inc. director G Jan Van Heek received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $4.68 per share and expire on June 2, 2036.
The 50,000 options vest in four equal quarterly installments, with one-quarter vesting three months after June 3, 2026 and additional quarters vesting every three months after that. Vesting requires continued service as a non-employee director on each vesting date.
Minerva Neurosciences director Hans Peter Hasler received a grant of stock options for 50,000 shares of common stock. The options have an exercise price of $4.68 per share and expire on June 2, 2036. Following the grant, he holds 50,000 options directly.
The award vests in four equal quarterly installments. One quarter of the options vests three months after June 3, 2026, with an additional quarter vesting every three months thereafter, as long as he continues serving as a non-employee director on each vesting date.
Minerva Neurosciences, Inc. reported results of its 2026 annual meeting, where stockholders approved amendments to its certificate of incorporation and bylaws. Investors backed an amendment limiting monetary liability of certain officers to the fullest extent permitted by Delaware law and another removing the company’s exclusive forum provision, both now reflected in a restated charter effective upon filing on June 4, 2026. The board also adopted amended and restated bylaws with technical and conforming updates, effective June 3, 2026. Stockholders approved all routine items, including director elections, executive compensation on an advisory basis, holding future say‑on‑pay votes annually, and ratifying Deloitte & Touche LLP as auditor. A total of 43,934,706 shares of common stock were entitled to vote as of the April 9, 2026 record date.
Minerva Neurosciences, Inc. entered a new at-the-market stock offering program with Leerink Partners, allowing the company to sell up to $75.0 million of common stock from time to time under an effective shelf registration. Leerink will receive a 3.0% commission on gross proceeds for any shares sold and is not obligated to sell a specific amount, while Minerva is not required to issue any shares and may suspend or terminate the program at its discretion.
Minerva also provided an update on its Phase 3 C19 trial of roluperidone for negative symptoms of schizophrenia. Following additional FDA feedback, the relapse assessment phase was extended from 40 weeks to 52 weeks, with patients receiving either a daily 64 mg dose of roluperidone or antipsychotics after the 12‑week primary efficacy period. The company continues to expect topline efficacy results in the second half of 2027 and relapse assessment data in the second half of 2028.
Registers an $75,000,000 at‑the‑market offering of common stock. Under a Sales Agreement dated May 27, 2026, the company may sell up to $75,000,000 of its common stock from time to time through Leerink Partners as agent in an at the market offering. Sales may occur on Nasdaq at prevailing market prices; Leerink Partners will receive a 3.0% commission on gross proceeds.
The prospectus supplement cites 43,841,998 shares outstanding as of March 31, 2026, net tangible book value of $(263.9) million (or $(6.02) per share) as of that date, and illustrative as‑adjusted figures after a full $75.0 million raise. Net proceeds are intended for general corporate purposes including clinical development, working capital and potential acquisitions.